Grifols agreed the deal five years after supplying $50m in equity and development financing for the neurodegenerative disease therapy developer.

The single-cell diagnostics technology provider closed a series A round led by Lilly Asia Ventures that also featured Tencent.

Japan Post Investment Corporation and Astellas Venture Management backed a series C round that will fund preclinical and clincical trials of the company's radiotherapy system.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Boston Scientific owns more than 30% of the emphysema treatment device developer, which is targeting $86.3m in its offering.

Backed by Research Institute of Tsinghua University in Shenzhen, CoWin Biosciences supplies biological reagents for diagnostics and research applications.

QuantaMatrix is targeting $17.80 to $22.30 per share under a regulation permitting a listing on the basis of growth and technology potential.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

UT Southwestern-linked CNS disease drug developer Taysha has filed to raise up to $100m in an IPO, just weeks after its $96m series B.

The CNS disease drug developer has filed to raise up to $100m in an initial public offering, just weeks after raising $96m from investors including GV.